Aprea Therapeutics (NASDAQ:APRE) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Aprea Therapeutics (NASDAQ:APRE) issued its earnings results on Monday. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.05, Yahoo Finance reports. Aprea Therapeutics had a negative net margin of 1,317.82% and a negative return on equity of 56.78%. The firm had revenue of $0.56 million for the quarter, compared to analysts’ expectations of $0.10 million.

Aprea Therapeutics Stock Up 2.5 %

Shares of Aprea Therapeutics stock opened at $3.30 on Wednesday. The business has a 50 day moving average of $3.95 and a 200 day moving average of $5.26. Aprea Therapeutics has a 52 week low of $3.20 and a 52 week high of $8.85. The company has a market cap of $17.92 million, a PE ratio of -0.99 and a beta of 1.04.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Aprea Therapeutics in a report on Monday. Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Aprea Therapeutics in a report on Tuesday.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.